MediPal Holdings Corporation

7459

JP3268950007

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 11:30:00 10/05/2024 am IST			5-day change	1st Jan Change
2,477 ^JPY	+0.34%		-0.24%	+8.38%

30/04	MediPal Holdings Corporation agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. for ¥3.8 billion.	CI
2023	Tranche Update on MediPal Holdings Corporation's Equity Buyback Plan announced on May 12, 2023.	CI

Orizuru Therapeutics Inc. announced that it has received funding from Kyoto University Innovation Capital Co., Ltd., SMBC Venture Capital Co., Ltd., MediPal Holdings Corporation

August 10, 2021

Orizuru Therapeutics Inc. announced that it has received a round of funding on August 10, 2021. The transaction included participation from MediPal Holdings Corporation and new investors Kyoto University Innovation Capital Co., Ltd. and SMBC Venture Capital Co., Ltd.

Latest news about MediPal Holdings Corporation

MediPal Holdings Corporation agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. for ¥3.8 billion.	30/04	CI
Tranche Update on MediPal Holdings Corporation's Equity Buyback Plan announced on May 12, 2023.	18/12	CI
MediPal Holdings Corporation's Equity Buyback announced on May 12, 2023 has closed with 4,171,900 shares, representing 1.97% for ¥9,999.86 million.	18/12	CI
Tranche Update on MediPal Holdings Corporation's Equity Buyback Plan announced on May 12, 2023.	03/23/03	CI
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Conclude Two Agreements on Mucopolysaccharidosis Type IIIB Treatment	28/23/28	CI
Tranche Update on MediPal Holdings Corporation's Equity Buyback Plan announced on May 12, 2023.	03/23/03	CI
MediPal Holdings Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	12/23/12	CI
MediPal Holdings Corporation announces an Equity Buyback for 5,800,000 shares, representing 2.71% for ¥10,000 million.	12/23/12	CI
MediPal Holdings Corporation authorizes a Buyback Plan.	12/23/12	CI
Japan Index Rises on Oil Price Surge; Polaris Appoints President, CFO	03/23/03	MT
Sumitomo Pharma Closes Sale of Food, Chemical Subsidiary to Medipal	03/23/03	MT
MediPal Holdings Corporation acquired Toshichi Co.,Ltd.	03/23/03	CI
MediPal Holdings Corporation completed the acquisition of Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd..	31/23/31	CI
Layered Co., Ltd. announced that it has received funding from MediPal Holdings Corporation, FFG Venture Business Partners Co., Ltd.	16/23/16	CI
Nichi-Iko Pharmaceutical Secures 98.5 Billion Yen of Debt Relief, Plans 20 Billion Yen Share Allotment; Shares Plunge 20%	30/22/30	MT
MediPal Holdings Corporation entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd..	30/22/30	CI
MEDIPAL and JCR Agree on the Granting of Exclusive Negotiation Rights for Global Commercialization Targeting Four Ultra-Rare Diseases and Concl	31/22/31	CI
MediPal Holdings Corporation acquired an unknown minority stake in Toshichi Co.,Ltd for ¥8.6 billion.	29/22/29	CI
Shinyei Kaisha announced that it expects to receive ¥170.7615 million in funding from MediPal Holdings Corporation	21/21/21	CI
Nichi-Iko Pharmaceutical Co., Ltd. announced that it has received ¥5.23102 billion in funding from MediPal Holdings Corporation	02/21/02	CI
Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive ¥5.23102 billion in funding from MediPal Holdings Corporation	17/21/17	CI
Orizuru Therapeutics Inc. announced that it has received funding from Kyoto University Innovation Capital Co., Ltd., SMBC Venture Capital Co., Ltd., MediPal Holdings Corporation	10/21/10	CI
Heartseed Inc. announced that it has received ¥4 billion in funding from a group of investors	11/21/11	CI
CARADA medica Inc. announced that it expects to receive ¥6.157 billion in funding from MTI Ltd., MediPal Holdings Corporation	16/21/16	CI
MediPal Holdings Corporation Partners with Cryoport, Inc. to Bring Temperature-Controlled Supply Chain Solutions to the Japanese Market	04/20/04	CI

Chart MediPal Holdings Corporation

Duration

Period

More charts

Company Profile

MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.

Sector

Pharmaceuticals

Calendar

14/05/2024 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for MediPal Holdings Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2,477 JPY

Average target price

2,593 JPY

Spread / Average Target

+4.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
MEDIPAL HOLDINGS CORPORATION	+8.38%	3.33B
MCKESSON CORPORATION	+20.94%	72.16B
CARDINAL HEALTH, INC.	-1.26%	23.88B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+8.25%	8.35B
SINOPHARM GROUP CO. LTD.	+5.13%	8.29B
HUADONG MEDICINE CO., LTD	-19.42%	8.18B
H. LUNDBECK A/S	+5.56%	4.81B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+16.83%	4.4B
EBOS GROUP LIMITED	-1.83%	4B
GALENICA AG	-1.65%	3.92B

Pharmaceuticals Wholesale

MediPal Holdings Corporation

Equities

7459

JP3268950007

Pharmaceuticals

Orizuru Therapeutics Inc. announced that it has received funding from Kyoto University Innovation Capital Co., Ltd., SMBC Venture Capital Co., Ltd., MediPal Holdings Corporation

EPS Revisions